<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446809</url>
  </required_header>
  <id_info>
    <org_study_id>7487</org_study_id>
    <secondary_id>NCI-2011-02488</secondary_id>
    <secondary_id>7487</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT01446809</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma</brief_title>
  <official_title>The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy
      and surgery in treating patients with soft tissue sarcoma. Pazopanib hydrochloride may stop
      the growth of tumor cells by blocking some of the enzymes that are needed for cell growth and
      may also stop the growth of soft tissue sarcoma by blocking blood flow to the tumor. Giving
      pazopanib hydrochloride and chemotherapy before surgery may make the tumor smaller and reduce
      the amount of tissue that needs to be removed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the absolute values and changes in standardized uptake values (SUV) by
      fludeoxyglucose F18 (FDG)-positron emission tomography (PET) before and after a 14 day Run-in
      period of pazopanib (pazopanib hydrochloride) versus placebo, and to compare this to the
      change in SUV following pre-operative chemotherapy.

      II. To evaluate the correlation between antiangiogenic activity and pazopanib drug exposure.

      III. To assess the response rate by Response Evaluation Criteria In Solid Tumors (RECIST)
      criteria after the 14 day Run-in period of pazopanib versus placebo and compare this to the
      response rate following pre-operative chemotherapy.

      SECONDARY OBJECTIVES:

      I. To examine the activity of antiangiogenic therapy with pazopanib combined with
      pre-operative chemotherapy for high risk extremity soft tissue sarcomas as measured by:
      histological necrosis at surgery; change in plasma and tumor biomarker assays of angiogenesis

      II. To evaluate the safety of sequential treatment with pazopanib and pre-operative
      chemotherapy with doxorubicin (doxorubicin hydrochloride) and ifosfamide.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive pazopanib hydrochloride orally (PO) once daily (QD). Treatment
      continues for 14 days in the absence of disease progression or unacceptable toxicity.

      ARM II: Patients receive placebo PO QD. Treatment continues for 14 days in the absence of
      disease progression or unacceptable toxicity.

      All patients then receive neoadjuvant chemotherapy comprising doxorubicin hydrochloride
      intravenously (IV) continuously over days 1-3 and ifosfamide IV on days 1-5. Treatment
      repeats every 21 days for 4 courses. Beginning 2-4 weeks later, all patients undergo surgery
      followed by 2 more courses of chemotherapy 2-4 weeks after completion of surgery. Some
      patients may also undergo adjuvant external beam radiation therapy 5 days a week for 5 days
      followed by a boost. Patients treated on Arm I may resume pazopanib hydrochloride 1 week
      after completion of all adjuvant therapy for up to 1 year. Treatment continues in the absence
      of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo</measure>
    <time_frame>From baseline to 15 days</time_frame>
    <description>Change in maximum SUV (standardized uptake value) of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy</measure>
    <time_frame>From baseline to 8 weeks</time_frame>
    <description>Change in maximum SUV of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response by RECIST Criteria</measure>
    <time_frame>At 15 days</time_frame>
    <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor Response by RECIST Criteria</measure>
    <time_frame>At 8 weeks</time_frame>
    <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Profile of Pazopanib</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>Trough plasma pazopanib concentration measured during the 14 day run-in period on days 10 through 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Levels of VEGF and Soluble VEGFR2 Assessed by ELISA on Plasma and Tumor Extracts</measure>
    <time_frame>At baseline and after 14 days</time_frame>
    <description>Plasma will be collected for measurement of VEGF and soluble VEGFR2 (sVEGFR2) at baseline, after the 14 day Run-in period of pazopanib, after completion of neoadjuvant chemotherapy and approximately every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated. Quantitative enzyme-linked immunosorbent assays (ELISA) for VEGF and sVEGFR2 will be performed on plasma and tumor extracts. Plasma will also be collected for micro RNA at baseline, after the 14 day Run-in period of pazopanib, following neoadjuvant chemotherapy and every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the interval of time from randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pathologic Response at the Time of Surgery as Measured by % Tumor Viability ( &gt;= 95% Necrosis)</measure>
    <time_frame>An expected average of 12 weeks</time_frame>
    <description>Estimate the amount of viable tumor, and report the percentage of necrosis. Analysis was only completed on a subset of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the duration of time from randomization to progressive disease (per RECIST), local recurrence, distant metastatic disease (exclusive of stage IV subjects), or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Stage IIA Adult Soft Tissue Sarcoma</condition>
  <condition>Stage III Adult Soft Tissue Sarcoma</condition>
  <condition>Stage IV Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External Beam Radiation Therapy</intervention_name>
    <description>Undergo external beam radiation therapy</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>Definitive Radiation Therapy</other_name>
    <other_name>EBRT</other_name>
    <other_name>External Beam Radiotherapy</other_name>
    <other_name>External Beam RT</other_name>
    <other_name>external radiation</other_name>
    <other_name>External Radiation Therapy</other_name>
    <other_name>external-beam radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>Asta Z 4942</other_name>
    <other_name>Asta Z-4942</other_name>
    <other_name>Cyfos</other_name>
    <other_name>Holoxan</other_name>
    <other_name>Holoxane</other_name>
    <other_name>Ifex</other_name>
    <other_name>IFO</other_name>
    <other_name>IFO-Cell</other_name>
    <other_name>Ifolem</other_name>
    <other_name>Ifomida</other_name>
    <other_name>Ifomide</other_name>
    <other_name>Ifosfamidum</other_name>
    <other_name>Ifoxan</other_name>
    <other_name>IFX</other_name>
    <other_name>Iphosphamid</other_name>
    <other_name>Iphosphamide</other_name>
    <other_name>Iso-Endoxan</other_name>
    <other_name>Isoendoxan</other_name>
    <other_name>Isophosphamide</other_name>
    <other_name>Mitoxana</other_name>
    <other_name>MJF 9325</other_name>
    <other_name>MJF-9325</other_name>
    <other_name>Naxamide</other_name>
    <other_name>Seromida</other_name>
    <other_name>Tronoxal</other_name>
    <other_name>Z 4942</other_name>
    <other_name>Z-4942</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <other_name>GW786034B</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Arm I (pazopanib hydrochloride)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and
             embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewing's,
             osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer
             (AJCC) (6th Edition) Stage III or T2a Stage II or Stage IV treatment naive patients
             planned for resection of the primary tumor, with resectable metastatic disease

          -  Measurable disease greater than 5 centimeters in greatest dimension; measurable
             lesions are defined as those that can be accurately measured in at least one dimension
             (longest diameter for non-nodal lesions and short axis for nodal lesions to be
             recorded) by chest x-ray, computed tomography (CT) scan, magnetic resonance imaging
             (MRI) or with calipers by clinical exam; all tumor measurements must be recorded in
             millimeters (or decimal fractions of centimeters)

          -  Intermediate or high grade lesions: 2 or 3 on a scale of 1-3 or grades 2 to 4 on a
             scale of 1-4

          -  Sarcoma located on upper (includes shoulder) or lower (includes hip) extremities or on
             the body wall

          -  Life expectancy of greater than 6 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1

          -  Karnofsky &gt;= 80%

          -  No prior chemotherapy, radiotherapy, or antiangiogenic therapy

          -  Absolute neutrophil count (ANC) &gt;= 1500/uL

          -  Hemoglobin (Hgb) &gt;= 9.0 g/dL

          -  Platelets &gt;= 100,000/uL

          -  Creatinine =&lt; 1.5 x upper limit of normal (ULN)

          -  Bilirubin =&lt; 1.5 mg/dL

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 1.5 x ULN

          -  Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time
             (PTT) within 1.2 X the ULN unless a subject is receiving Coumadin and has stable INR
             which is in range for the desired level of anticoagulation

          -  Left ventricular ejection fraction (LVEF) &gt;= 50%

          -  Blood pressure (BP) no greater than 140 mmHg (systolic) and 90 mmHg (diastolic) for
             eligibility; initiation or adjustment of BP medication is permitted prior to study
             entry provided that the average of three BP readings on baseline assessment prior to
             enrollment is less than 140/90 mmHg

          -  Eligibility of subjects receiving any medications or substances known to affect or
             with the potential to affect the activity or pharmacokinetics of pazopanib will be
             determined following review of their cases by the Principal Investigator

          -  Women of child-bearing potential and men must agree to use adequate contraception

          -  A female is eligible to enter and participate in this study if she is of
             non-childbearing potential (i.e., physiologically incapable of becoming pregnant) or
             if she is of childbearing potential

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Subjects with known brain metastases and/or unresectable sarcoma

          -  Uncontrolled intercurrent illness including, active serious infection, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac ventricular arrhythmia
             requiring anti-arrhythmic therapy, serious hepatic impairment, or psychiatric
             illness/social situations that would limit compliance with study

          -  Pregnant or lactating women

          -  Subjects with no additional active malignancy within the last 3 years

          -  Subjects receiving other investigational agents

          -  Subjects with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to pazopanib or other agents used in the study

          -  Subjects who have both bilirubin &gt; ULN and AST/ALT &gt; ULN

          -  Subjects with a urine protein/creatinine ratio greater than 1

          -  Subjects with a baseline corrected QT (QTc) of equal to or greater than 480 msecs or
             other significant electrocardiogram (ECG) abnormalities

          -  Certain medications that act through the cytochrome P450 (CYP450) system are
             specifically prohibited in subjects receiving pazopanib and others should be avoided
             or administered with extreme caution and require principal investigator (PI) approval

               -  Strong inhibitors of CYP3A4 such as ketoconazole, itraconazole, clarithromycin,
                  atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir,
                  telithromycin, voriconazole may increase pazopanib concentrations and are
                  prohibited; grapefruit juice is also an inhibitor of CYP450 and should not be
                  taken with pazopanib

               -  Strong inducers of CYP3A4, such as rifampin, may decrease pazopanib
                  concentrations, are prohibited

               -  Medications which have narrow therapeutic windows and are substrates of CYP3A4,
                  CYP2D6, or CYP2C8 should be avoided and, if necessary, administered with caution

               -  Pazopanib, 800 mg once daily, has no effect on CYP2C9, CYP1A2, or CYP2C19 in vivo
                  but does in vitro; therefore, therapeutic doses of warfarin, a substrate of
                  CYP2C9, and omeprazole, a substrate of CYP2C19 are permitted; caffeine, a
                  substrate of CYP1A2, is also permitted

          -  Certain medications that are associated with a risk for QTc prolongation and/or
             Torsades de Pointes, although not prohibited, should be avoided or replaced with
             medications that do not carry these risks, if possible

          -  Subjects who require heparin other than low-molecular weight heparin

          -  Subjects with any condition that may impair the ability to swallow or absorb oral
             medications/investigational product including:

               -  Any lesion, whether induced by tumor, radiation or other conditions, which makes
                  it difficult to swallow capsules or pills

               -  Prior surgical procedures affecting absorption including, but not limited to
                  major resection of stomach or small bowel

               -  Active peptic ulcer disease, not on a proton pump inhibitor

               -  Malabsorption syndrome

          -  Subjects with any condition that may increase the risk of gastrointestinal bleeding or
             gastrointestinal perforation, including

               -  Active peptic ulcer disease, not on a proton pump inhibitor

               -  Known intraluminal metastatic lesions

               -  Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or

               -  Other gastrointestinal conditions which increase the risk of perforation

               -  History of abdominal fistula, gastrointestinal perforation or intra-abdominal
                  abscess within 28 days prior to beginning study treatment

          -  Subjects with any of the following cardiovascular conditions within the past 6 months:

               -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA)

               -  Cardiac arrhythmia

               -  Admission for unstable angina

               -  Cardiac angioplasty or stenting

               -  Coronary artery bypass graft surgery

               -  Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been
                  treated with therapeutic anticoagulation for less than 6 weeks

               -  Arterial thrombosis

               -  Symptomatic peripheral vascular disease

               -  Class III or IV heart failure as defined by the New York Heart Association (NYHA)
                  functional classification system; a subject who has a history of Class II heart
                  failure and is asymptomatic on treatment may be considered eligible

          -  History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to
             first dose of study drug

          -  History of serious or non-healing wound, ulcer, or bone fracture

          -  Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral
             therapy are ineligible

          -  Subjects with severe hepatic impairment

               -  Bilirubin &gt; 3 x ULN, regardless of any level of ALT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darin Davidson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 12, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <results_first_submitted>September 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2019</results_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Isophosphamide mustard</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT01446809/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pazopanib</title>
          <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="P3">
          <title>Blinded</title>
          <description>Patients receive pazopanib hydrochloride or placebo PO QD. Patient did not complete study and thus treatment arm remains blinded.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to complete study procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pazopanib</title>
          <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" lower_limit="21" upper_limit="70"/>
                    <measurement group_id="B2" value="61" lower_limit="37" upper_limit="75"/>
                    <measurement group_id="B3" value="53" lower_limit="21" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Screening SUV</title>
          <units>Standardized Uptake Value- SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" lower_limit="2.3" upper_limit="38.7"/>
                    <measurement group_id="B2" value="9.9" lower_limit="2.7" upper_limit="15.6"/>
                    <measurement group_id="B3" value="8.3" lower_limit="2.3" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo</title>
        <description>Change in maximum SUV (standardized uptake value) of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
        <time_frame>From baseline to 15 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo</title>
          <description>Change in maximum SUV (standardized uptake value) of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
          <units>Standardized uptake value-SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-14.7" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-2.2" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy</title>
        <description>Change in maximum SUV of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
        <time_frame>From baseline to 8 weeks</time_frame>
        <population>8 week PET not done on one Pazopanib participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Maximum SUV of Tumors Measured by FDG-PET Post Receipt of 2 Courses of Preoperative Chemotherapy</title>
          <description>Change in maximum SUV of tumors measured by FDG-PET. Comparison conducted using a two-sided Wilcoxon rank sum test.</description>
          <population>8 week PET not done on one Pazopanib participant.</population>
          <units>SUV</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-32.7" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-4.0" lower_limit="-11.2" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response by RECIST Criteria</title>
        <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>At 15 days</time_frame>
        <population>Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the LD of target lesions; Progression (PD),20% increase in the sum of the LD of target lesions,or measurable increase in a non-target lesion,or appearance of new lesions.&quot;,</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response by RECIST Criteria</title>
          <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the LD of target lesions; Progression (PD),20% increase in the sum of the LD of target lesions,or measurable increase in a non-target lesion,or appearance of new lesions.&quot;,</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tumor Response by RECIST Criteria</title>
        <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
        <time_frame>At 8 weeks</time_frame>
        <population>8 week MRI not done on one Placebo patient.</population>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response by RECIST Criteria</title>
          <description>RECIST measurements will be performed on serial MRIs to evaluate the correlation with FDG-PET. The longest diameter (LD) of the target lesions will be measured and reported as the baseline LD. The baseline LD will be used as reference to further characterize the objective tumor response of the measurable dimension of the disease.Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Progression (PD), a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions</description>
          <population>8 week MRI not done on one Placebo patient.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Profile of Pazopanib</title>
        <description>Trough plasma pazopanib concentration measured during the 14 day run-in period on days 10 through 14.</description>
        <time_frame>Up to 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile of Pazopanib</title>
          <description>Trough plasma pazopanib concentration measured during the 14 day run-in period on days 10 through 14.</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.38" spread="0.94"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Levels of VEGF and Soluble VEGFR2 Assessed by ELISA on Plasma and Tumor Extracts</title>
        <description>Plasma will be collected for measurement of VEGF and soluble VEGFR2 (sVEGFR2) at baseline, after the 14 day Run-in period of pazopanib, after completion of neoadjuvant chemotherapy and approximately every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated. Quantitative enzyme-linked immunosorbent assays (ELISA) for VEGF and sVEGFR2 will be performed on plasma and tumor extracts. Plasma will also be collected for micro RNA at baseline, after the 14 day Run-in period of pazopanib, following neoadjuvant chemotherapy and every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated.</description>
        <time_frame>At baseline and after 14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Levels of VEGF and Soluble VEGFR2 Assessed by ELISA on Plasma and Tumor Extracts</title>
          <description>Plasma will be collected for measurement of VEGF and soluble VEGFR2 (sVEGFR2) at baseline, after the 14 day Run-in period of pazopanib, after completion of neoadjuvant chemotherapy and approximately every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated. Quantitative enzyme-linked immunosorbent assays (ELISA) for VEGF and sVEGFR2 will be performed on plasma and tumor extracts. Plasma will also be collected for micro RNA at baseline, after the 14 day Run-in period of pazopanib, following neoadjuvant chemotherapy and every 3 months thereafter until completion of pazopanib maintenance therapy, when indicated.</description>
          <units>percentage of concentration</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">PI left institution and this data was not analyzed.</measurement>
                    <measurement group_id="O2" value="NA">PI left institution and this data was not analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Defined as the interval of time from randomization until death from any cause.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Defined as the interval of time from randomization until death from any cause.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pathologic Response at the Time of Surgery as Measured by % Tumor Viability ( &gt;= 95% Necrosis)</title>
        <description>Estimate the amount of viable tumor, and report the percentage of necrosis. Analysis was only completed on a subset of participants.</description>
        <time_frame>An expected average of 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pazopanib</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathologic Response at the Time of Surgery as Measured by % Tumor Viability ( &gt;= 95% Necrosis)</title>
          <description>Estimate the amount of viable tumor, and report the percentage of necrosis. Analysis was only completed on a subset of participants.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <description>Defined as the duration of time from randomization to progressive disease (per RECIST), local recurrence, distant metastatic disease (exclusive of stage IV subjects), or death, whichever occurs first.</description>
        <time_frame>Up to 3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Pazopanib Hydrochloride)</title>
            <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV
External Beam Radiation Therapy: Undergo external beam radiation therapy
Ifosfamide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pazopanib Hydrochloride: Given PO
Pharmacological Study: Correlative studies
Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Placebo)</title>
            <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV
External Beam Radiation Therapy: Undergo external beam radiation therapy
Ifosfamide: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pharmacological Study: Correlative studies
Placebo: Given PO
Therapeutic Conventional Surgery: Undergo surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <description>Defined as the duration of time from randomization to progressive disease (per RECIST), local recurrence, distant metastatic disease (exclusive of stage IV subjects), or death, whichever occurs first.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pazopanib</title>
          <description>Patients receive pazopanib hydrochloride PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pazopanib Hydrochloride: Given PO Pharmacological Study: Correlative studies Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive placebo PO QD. Treatment continues for 14 days in the absence of disease progression or unacceptable toxicity.
Doxorubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo external beam radiation therapy Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Placebo: Given PO Therapeutic Conventional Surgery: Undergo surgery</description>
        </group>
        <group group_id="E3">
          <title>Blinded</title>
          <description>Patients receive pazopanib hydrochloride or placebo PO QD. Patient did not complete study and thus treatment arm remains blinded.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Left gluteal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumor Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral pulmonary emboli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Darin Davidson</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-543-3690</phone>
      <email>djdavi@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

